Join the Oncology Voice Network. Join for Free
Pushing the Limits of Cancer Research and Surgery
City of Hope Academic Research pancreatic cancer

Pushing the Limits of Cancer Research and Surgery


Share This Article



Summary

Dr. Mustafa Raoof on PIPAC, pancreatic cancer research, and how global innovation can shape the next chapter of surgical oncology.

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Dr. Monty Pal talks with Mustafa Raoof, a leading surgical oncologist and physician-scientist at City of Hope, about the challenges and potential in treating some of the toughest cancers.

Dr. Raoof reflects on his path - from boarding school in Pakistan to pioneering new techniques in peritoneal metastasis treatment at a world renowned cancer center, including the promising intraperitoneal therapy known as Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). He breaks down his lab's latest work on DNA repair in pancreatic cancer, shares his perspectives on the value of making research more accessible across low-resource settings, and discusses how he balances life as a researcher, surgeon, and his most important role as a dad.

This is a grounded, thoughtful conversation that spotlights how innovation meets real-world limitations, and why collaboration  —not just within institutions, but across borders — is more essential than ever.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Partner Avatar Monty Pal

What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.

Podcast
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Partner Avatar Monty Pal

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN